18 December 2018
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Sativa Investments PLC
(“Sativa” or the “Company”)
Investee business Rapid Dose Therapeutics lists on the Canadian Securities Exchange
Sativa Investments PLC (NEX: SATI),the UK’s first medicinal cannabis investment vehicle,announces that shares in its investee business, Rapid Dose Therapeutics Inc. (“RDT”), the Toronto-based Pharma-Tech company, are now listed on the Canadian Securities Exchange (“CSE”) under the symbol DOSE. RDT’s shares were admitted to the CSE yesterday, Monday 17th December 2018.
Full details of the Company’s investment in RDT are included in its release of 23rd May 2018. At that time, Sativa subscribed for 400,000 RDT shares at C$ 0.50 per share, at a cost of C$ 0.2 million cash. The closing price of RDT’s shares on the CSE yesterday was C$ 0.85.
Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “RDT’s expeditious move to the highly respected CSE reflects the worldwide interest in the fast-developing medicinal cannabis industry.
“It’s very pleasing to see Sativa’s second investment presenting an initial paper profit for the Company of CS$ 0.14 million, a rise of 70 per cent, after only seven months.
“RDT’s technology has very positive implications for both Sativa’s medicinal cannabis business and its CBD-focused 100 per cent subsidiary George Botanicals Limited, and we look forward to continued collaboration with RDT alongside our investment.”
RDT has its own patent-pending proprietary QuickStrip™ technology, a fast-dissolving strip that is placed on or under the tongue, or inside the cheek, which allows medication to enter directly in to the recipient’s system, mimicking an injection path. Pharmaceuticals, emulsified oils and over-the-counter medicines are used in RDT’s proprietary RDMx mixture technology, which is sold across North America.
The Directors of the Company accept responsibility for the contents of this announcement.
– Ends –
For further information please contact:
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
NEX Exchange Corporate Adviser
Guy Miller and Lucy Williams
Peterhouse Capital Limited
+44 (0) 20 7469 0930
Notes to Editors
Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted. Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.
The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa acquires can either be public or private.
Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company,Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.
The Company has a presence in Germany through its joint venture with Germany’s Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in to produce medicinal cannabis and CBD products.
The Company also has an option to lease a glasshouse facility in Wiltshire, with an up to 298,806 sq ft build out potential, togrow cannabis plants to produce medicinal cannabis and CBD products, which by law must contain a maximum 0.2 per cent THC. The Company’s Chief Executive Officer, Geremy Thomas, has a UK hemp growers licence.
Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.
The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.
For more information on Sativa Investments, please visit: www.sativagroup.co.uk